- Home
- UPXI vs NRXS Comparison
UPXI vs NRXS Comparison
Compare UPXI & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPXI | NRXS |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 82.0M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | UPXI | NRXS |
|---|---|---|
| Price | $0.77 | $7.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 2.4M | 140.1K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,998,028.00 | $3,569,282.00 |
| Revenue This Year | $6.81 | $132.54 |
| Revenue Next Year | $63.30 | $138.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 58.10 | 32.89 |
| 52 Week Low | $0.54 | $2.21 |
| 52 Week High | $5.25 | $9.33 |
Technical Indicators
Market Signals| Indicator | UPXI | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 25.33 | 55.65 |
| Support Level | $0.74 | $6.60 |
| Resistance Level | $0.91 | $7.75 |
| Average True Range (ATR) | 0.07 | 0.45 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 3.02 | 73.17 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. The company is in the cryptocurrency industry and the management of cash assets through a cryptocurrency portfolio, principally focused in Solana tokens and generating a yield from the treasury, principally through staking of those tokens. Geographically, the company generates the majority of its revenue from the United States. The firm generates the majority of its revenue from the Digital Asset revenue.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).